Acromegaly

Chapter

Abstract

Acromegaly is a rare chronic condition with an approximate incidence of 5 cases per million per year and a prevalence of 60 cases per million (Lugo et al., Int J Endocrinol 2012: 540398, 2012). In modern literature, the condition was first described by the French neurologist Pierre Marie in 1886, with acromegaly being from the Greek akron—extremities and megas—large (Marie, Rev de med 6:297–333, 1886). Acromegaly is a consequence of excess growth hormone (GH) secretion, typically due to a benign pituitary adenoma, usually macrodenomas (>10 mm in diameter). Rarely can it occur as a result of excess secretion of growth hormone releasing hormone (GHRH) from the hypothalamus (Asa et al., J Clin Endocrinol Metab 58:796–803, 1984) or from neuroendocrine tumours (Gola et al., Pituitary 9(3):221–9, 2006). Most cases are sporadic but it can be a manifestation of familial syndromes such as multiple endocrine neoplasia type 1, McCune Albright syndrome, familial acromegaly and Carney’s syndrome. Mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene have recently been associated with a predisposition to familial pituitary adenoma, and in particular acromegaly.

Acromegaly results in increased morbidity and premature mortality, but these can be reduced if the disease is controlled. This chapter describes the physiology of GH secretion, the causes and clinical features of acromegaly, the diagnostic tests and treatment.

Keywords

Dopamine Sludge Adenoma Cortisol Angiotensin 

References

  1. 1.
    Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol. 2012;2012:540398.PubMedCrossRefGoogle Scholar
  2. 2.
    Marie P. Sur deux cas d’acromegalie; hypertrophie singuliere non congenitale des extremites superieures, inferieures et cephalique. Rev Med. 1886;6:297–333.Google Scholar
  3. 3.
    Asa SL, Scheithauer BW, Bilbao JM, et al. A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone releasing factor. J Clin Endocrinol Metab. 1984;58:796–803.PubMedCrossRefGoogle Scholar
  4. 4.
    Gola M, Doga M, Bonadonna S, Mazziotti G, Vescovi PP, Giustina A. Neuroendocrine tumors secreting growth hormone-releasing hormone: pathophysiological and clinical aspects. Pituitary. 2006;9(3):221–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Bloch B, Brazeau P, Ling N, Bohlen P, Esch F, Wehrenberg WB. Immunohistochemical detection of growth hormone releasing factor in brain. Nature. 1983;301:607–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Merchenthaler I, Vigh S, Schally AV, Petrusz P. Immunocytochemical localization of growth hormone-releasing factor in the rat hypothalamus. Endocrinology. 1984;114:1082–108.PubMedCrossRefGoogle Scholar
  7. 7.
    Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocr Rev. 1986;7:223–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. 1994;35 Suppl 3:S1–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Horvath S, Palkovits M, Gorcs T, Arimura A. Electron microscopic immunocytochemical evidence for the existence of bidirectional synaptic connections between growth hormone and somatostatin-containing neurons in the hypothalamus of the rat. Brain Res. 1989;481:8–15.PubMedCrossRefGoogle Scholar
  10. 10.
    Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19:717–97.PubMedCrossRefGoogle Scholar
  11. 11.
    Kojima M, Hosoda H, Date Y, Naka-zato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.PubMedCrossRefGoogle Scholar
  12. 12.
    Toshinai K, Mondal MS, Nakazato M, Date Y, Murakami N, Kojima M, Kangawa K, Matsukura S. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia and leptin administration. Biochem Biophys Res Commun. 2001;281:1220–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Clemmons D. Insulin-like growth factor 1 and its binding proteins. In: DeGroot LJ, Jameson JL, editors. Endocrinology. Philadelphia, PA: Elsevier Saunders; 2006. p. 643–73.Google Scholar
  14. 14.
    Melmed S, et al. IGF-I receptor signalling: lessons from the somatotroph. Recent Prog Horm Res. 1996;51:189–215. discussion 215–186.PubMedGoogle Scholar
  15. 15.
    Yan H, Guo ZY, Gong XW, Xi D, Feng YM. A peptide model of insulin folding intermediate with one disulfide. Protein Sci. 2003;12(4):768–75.PubMedCrossRefGoogle Scholar
  16. 16.
    Clemmons DR. IGF binding proteins and their functions. Mol Reprod Dev. 1993;35(4):368–74.PubMedCrossRefGoogle Scholar
  17. 17.
    Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol. 2001;170(1):63–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Melmed S. Acromegaly. N Eng J Med. 2006;355(24):2558–73.CrossRefGoogle Scholar
  19. 19.
    Killinger Z, Payer J, Lazúrová I, et al. Arthropathy in acromegaly. Rheum Dis Clin North Am. 2010;36(4):713–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Nagulesparen M, Trickey R, Davies MJ, Jenkins JS. Muscle changes in acromegaly. Br Med J. 1976;2(6041):914–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis. 2008;3:17.PubMedCrossRefGoogle Scholar
  22. 22.
    Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–52.PubMedCrossRefGoogle Scholar
  23. 23.
    Deray G, Chanson P, Maistre G, Warnet A, Eurin J, Barthelemy C, Masson F, Martinez F, Lubetzki J, Legrand JC. Atrial natriuretic factor in patients with acromegaly. Eur J Clin Pharmacol. 1990;38:409–13.PubMedCrossRefGoogle Scholar
  24. 24.
    Kamenicky P, et al. Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology. 2008;149(7):3294–305.PubMedCrossRefGoogle Scholar
  25. 25.
    Fazio S, Cittadini A, Biondi B, Palmieri EA, Riccio G, Bone F, Oliviero U, Sacca L. Cardiovascular effects of short-term growth hormone hypersecretion. J Clin Endocrinol Metab. 2000;85(1):179–82.PubMedCrossRefGoogle Scholar
  26. 26.
    Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab. 1997;82:2777–81.PubMedCrossRefGoogle Scholar
  27. 27.
    Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf). 2001;54(2):137–54.CrossRefGoogle Scholar
  28. 28.
    Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, Meyer J. Arrhythmia profile in acromegaly. Eur Heart J. 1992;13:51–6.PubMedGoogle Scholar
  29. 29.
    Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab. 2003;88(7):3196–201.PubMedCrossRefGoogle Scholar
  30. 30.
    Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab. 2004;89:71–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Barkan AL, Stred SE, Reno K, et al. Increased growth hormone pulse frequency in acromegaly. J Clin Endocrinol Metab. 1989;69(6):1225–33.PubMedCrossRefGoogle Scholar
  32. 32.
    Greenman Y, Tordjman K, Kisch E, et al. Relative sparing of anterior pituitary function in patients with growth hormone-secreting macroadenomas: comparison with nonfunctioning macroadenomas. J Clin Endocrinol Metab. 1995;80(5):1577–83.PubMedCrossRefGoogle Scholar
  33. 33.
    Gasperi M, Martino E, Manetti L, et al. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest. 2002;25(3):240–5.PubMedGoogle Scholar
  34. 34.
    Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab. 1995;80:3395.PubMedCrossRefGoogle Scholar
  35. 35.
    Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ. Serum lipoprotein changes following IGF-1 normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol. 2002;56(3):303–11.CrossRefGoogle Scholar
  36. 36.
    Lund B, Eskildsen PC, Lund B, Norman AW, Sorenson OH. Calcium and vitamin D metabolism in acromegaly. Acta Endocrinol (Copenh). 1981;96(4):444–50.Google Scholar
  37. 37.
    Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab. 2001;86:2935–41.PubMedCrossRefGoogle Scholar
  38. 38.
    Melmed S. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab. 2001;86:2929–34.PubMedCrossRefGoogle Scholar
  39. 39.
    Renehan AG, Bhaskar P, Painter JE, O’Dwyer ST, Haboubi N, Varma J, Ball SG, Shalet SM. The prevalence and characteristics of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab. 2000;85:3417–24.PubMedCrossRefGoogle Scholar
  40. 40.
    Jenkins PJ, Frajese V, Jones AM, et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab. 2000;85(9):3218–21.PubMedCrossRefGoogle Scholar
  41. 41.
    Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom acromegaly study group. J Clin Endocrinol Metab. 1998;83(8):2730–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94:1509–17.PubMedCrossRefGoogle Scholar
  43. 43.
    Wieringa CE, Barth JH, Trainer PJ. Growth hormone assay standardization: a biased view? Clin Endocrinol. 2004;60:538–9.CrossRefGoogle Scholar
  44. 44.
    Brabant G, et al. Serum insulin like growth factor 1 reference values for an automated chemiluminescence immunoassay system: results from a multucenter study. Horm Res. 2003;60(2):53–60.PubMedCrossRefGoogle Scholar
  45. 45.
    Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab. 2005;90(7):4081–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89–95.PubMedCrossRefGoogle Scholar
  47. 47.
    Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89:667–74.PubMedCrossRefGoogle Scholar
  48. 48.
    Arosio M, The Italian Study Group of Acromegaly, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167(2):189–98.PubMedGoogle Scholar
  49. 49.
    Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab. 2004;89:2789–96.PubMedCrossRefGoogle Scholar
  50. 50.
    Swearingen B, Barker II FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83:3419–26.PubMedCrossRefGoogle Scholar
  51. 51.
    Freda PU, Nuruzzaman AT, Reyes CM, et al. Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab. 2004;89(2):495–500.PubMedCrossRefGoogle Scholar
  52. 52.
    Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S, Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Ahmed S, Elsheikh M, Stratton IM, et al. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 1999;50(5):561–7.CrossRefGoogle Scholar
  54. 54.
    Laws ER, Vance ML, Thapar K. Pituitary surgery for the management of acromegaly. Horm Res. 2000;53 Suppl 3:71–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Clayton RN, Stewart PM, Shalet SM, Wass JA. Pituitary surgery for acromegaly. Should be done by specialists. BMJ. 1999;319(7210):588–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Lissett C, Peacey S, Laing I, et al. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf). 1998;49:653–7.CrossRefGoogle Scholar
  57. 57.
    Wang YY, Higham C, Kearney T, Davis J, Trainer P, Gnanalingham K. Acromegaly surgery in Manchester revisited- The impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clin Endocrinol (Oxf). 2012;76:399–406.CrossRefGoogle Scholar
  58. 58.
    Ahmed S, Elsheikh M, Stratton IM, et al. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 1999;50:561–7.CrossRefGoogle Scholar
  59. 59.
    Marquez Y, Tuchman A, Zada G. Surgery and radiosurgery for acromegaly: a review of indications, operative techniques, outcomes, and complications. Int J Endocrinol. 2012;2012:386401.PubMedCrossRefGoogle Scholar
  60. 60.
    Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab. 2006;91(4):1239–45.PubMedCrossRefGoogle Scholar
  61. 61.
    Wass JA, Thorner MO, Morris DV, Rees LH, Mason AS, Jones AE, Besser GM. Long-term treatment of acromegaly with bromocriptine. Br Med J. 1977;1(6065):875–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens J, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327–35.PubMedCrossRefGoogle Scholar
  64. 64.
    Antonini A, Poewe W. Fibrotic heart valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6(9):826–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–98.PubMedCrossRefGoogle Scholar
  66. 66.
    Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004;61:209–15.CrossRefGoogle Scholar
  67. 67.
    Bevan JS, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab. 2002;87(10):4554–63.PubMedCrossRefGoogle Scholar
  68. 68.
    Carlsen SM, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. 2008;93(8):2984–90.PubMedCrossRefGoogle Scholar
  69. 69.
    Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, Maiter D. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004;151(3):317–24.PubMedCrossRefGoogle Scholar
  70. 70.
    Ashwell SG, Bevan JS, Edwards OM, Harris MM, Holmes C, Middleton MA, James RA. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol. 2004;150(4):473–80.PubMedCrossRefGoogle Scholar
  71. 71.
    Auriemma RS, Pivonello R, Galdiero M, De Martino MC, De Leo M, Vitale G, Lombardi G, Colao AJ. Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. J Endocrinol Invest. 2008;31(11):956–65.PubMedGoogle Scholar
  72. 72.
    van der Hoek J, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab. 2004;89:638–45.PubMedCrossRefGoogle Scholar
  73. 73.
    Colao A, et al. A 12 month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366(10):914–24.PubMedCrossRefGoogle Scholar
  74. 74.
    Chen WY, Wight DC, Wagner TE, Kopchick JJ. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci U S A. 1990;87:5061–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science. 1992;256:1677–80.PubMedCrossRefGoogle Scholar
  76. 76.
    Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone–receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171–7.PubMedCrossRefGoogle Scholar
  77. 77.
    van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brubach K, Stalla GK, Strasburger CJ, German Pegvisomant Observational Study. The German ACROSTUDY: past and present. Eur J Endocrinol. 2009;161 Suppl 1:S3–10.PubMedCrossRefGoogle Scholar
  79. 79.
    Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90(10):5684–91.PubMedCrossRefGoogle Scholar
  80. 80.
    van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012;97(5):1589–97.PubMedCrossRefGoogle Scholar
  81. 81.
    Trainer PJ. ACROSTUDY: the first 5 years. Eur J Endocrinol. 2009;161 Suppl 1:S19–24.PubMedCrossRefGoogle Scholar
  82. 82.
    Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90:5684–91.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Endocrinology, Manchester Academic Health Science CentreThe Christie NHS Foundation TrustManchesterUK

Personalised recommendations